|
|
 |
News Article |
| Resonance Health Signs MOU with Major US Radiology Chain |
September 13, 2005
|
13 September 2005: The Resonance Health Group (ASX: RHT) today announced that it has signed a Memorandum of Understanding (MOU) with a major radiology service provider in the United States for a pilot study in preparation for the commercial launch of its MRI-based liver-iron test, FerriScan®.
Under the proposed arrangement, the US radiology chain will perform the MRI component of the FerriScan test and will be responsible for billing and collection activities. Resonance Health will perform the FerriScan analysis. The parties will collaborate on launch plans and reimbursement strategy. US site activation under this collaboration is expected to commence in the fourth quarter of 2005.
The new partnership complements the continuing supply of FerriScan to US centres participating in clinical programs being conducted by Novartis and the Thalassemia Clinical Research Network.
Dr James Williams, Managing Director of Resonance Health said:
This partnership marks a major milestone in the global commercialisation of FerriScan with the intent to supply FerriScan through a significant number of US MRI sites. With our forthcoming profile activities, including the American Society of Hematology (ASH) and the American Association for the Study of Liver Disease (AASLD), held in the US during November and December respectively, we are positioned to begin building our US revenue stream. ASH and AASLD will attract more than 20,000 of the US and world's clinical specialists responsible for managing patients with iron disorders.
FerriScan represents a breakthrough in the diagnosis and management of iron overload, most prominently in disease states such as thalassemia and hemochromatosis which affect over two million people in the US alone. FerriScan provides doctors with information that is more accurate and cost effective than a liver biopsy or serum blood markers without the need for an invasive procedure and possible dangerous side effects.
Having too much iron in the body and being unable to get rid of this excess is one of the world's most common hereditary disorders. The disorders, often collectively termed as Iron Overload, are generally classified as primary (e.g. hereditary hemochromatosis HHC) or secondary (e.g. acquired transfusion related iron overload such as thalassemia). Approximately 11 million people globally, who have clinically significant iron loading would benefit from improved diagnosis and management of their condition. |
View all news articles |
|
